Evidence for the benefits of cardiovascular prevention, with lifestyle changes or with medications,1 is strong. However, recently released guidelines2-4 from the United States, Europe, and Canada have differing recommendations regarding which patients to treat with medications and whether to tailor treatment aiming for specific targets. Low-density lipoprotein cholesterol (LDL-C) levels are the focal point in this debate.
Ioannidis JPA. Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors. JAMA. 2017;318(5):419–420. doi:10.1001/jama.2017.6765
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: